Characteristics of patients with myasthenia gravis and the Lambert–Eaton myasthenic syndrome
| Myasthenia gravis (n=101) | Lambert–Eaton syndrome (n=38) | |
|---|---|---|
| *Thymoma in myasthenia gravis, small cell lung carcinoma in Lambert–Eaton syndrome. | ||
| †Anti-acetylcholine receptor antibodies in myasthenia gravis, or anti-P/Q-type voltage gated calcium channel antibodies in Lambert–Eaton syndrome. | ||
| ‡All 14 patients with Lambert–Eaton syndrome and small cell lung carcinoma received chemotherapy. | ||
| Male:female ratio (% male) | 36:65 (36) | 22:16 (58) |
| Age at onset (years ) (mean (range)) | 41 (5 to 78) | 50 (11 to 76) |
| Associated tumour* | 13 (13%) | 14 (37%) |
| Interval between disease onset and tumour diagnosis (months) (median (range)) | 8 (0 to 62) | 3 (1 to 54) |
| Disease specific antibody positive† | 72/97 (74%) | 32/36 (89%) |
| Immunosuppression or chemotherapy | 58/101 (58%) | 21/38 (55%)‡ |
| Follow up (years) (mean (range)) | 9 (1 to 42) | 7 (1 to 38) |